Cholesterol drug paired with immunotherapy shows promise for tough kidney cancer
NCT ID NCT06284564
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding evolocumab (a cholesterol-lowering drug) to nivolumab (an immunotherapy) can help control metastatic kidney cancer that has not responded to prior treatments. Only 10 participants are enrolled, and the main goal is to check safety and side effects. The study is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
evolocumab and nivolumab
What this could lead to
If it works, this could point toward a new combination therapy for advanced kidney cancer that has stopped responding to other treatments.
What could go wrong
This is a very small, early-phase trial with only 10 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States